MichaelBogenschutzMD

Psychiatry • New York, NY

Addiction, Psychopharmacology

Physician

Join to view full profile

Dr. Bogenschutz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bogenschutz's full profile

Already have an account?

Office
462 1st Avenue
New York, NY 10016
Phone+1 646-501-4026

Summary

Dr. Michael Bogenschutz is a psychiatrist in New York, NY.

Education & Training

Cambridge Health AllianceResidency, Psychiatry, 1990 - 1994
Harvard Medical SchoolClass of 1990, MD, Cum Laude

Certifications & Licensure

NY State Medical License 2015 - 2026
NM State Medical License 1994 - 2016
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Addiction Psychiatry

Clinical Trials

Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD Start of enrollment: 2019 Oct 16
Recruiting
Phase 2
Roles: Contact
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD Start of enrollment: 2024 Jul 01
Not yet recruiting
Phase 2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

17 citations
Benefit-cost analysis of SBIRT interventions for substance using patients in emergency departments
Brady P. Horn, Cameron Crandall, Alyssa A. Forcehimes, Michael T. French, Michael P. Bogenschutz
Journal of Substance Abuse Treatment. 2017-08-01
383 citations
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Jennifer M. Mitchell, Michael P. Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman
Nature Medicine. 2021-05-10
74 citations
Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses.
Michael P. Bogenschutz, Jessica M. Pommy
Drug Testing and Analysis. 2012-07-01

Press Mentions

B.More Collaborator, Dr. Michael Bogenschutz, Awarded $15 Million NIDA Grant for Landmark Psilocybin Study in Opioid Use DisorderOctober 31st, 2024
B.More Collaborator, Dr. Michael Bogenschutz, Awarded NIAAA Grant for Psilocybin in Alcohol Use Disorder Trial at NYU and Silver Hill HospitalSeptember 12th, 2024
FDA Rejection of MDMA-Assisted Therapy Rattles Advocates but Doesn’t Spell End of Psychedelics in Medicine, Experts SayAugust 13th, 2024